Last reviewed · How we verify

NCT04063254

A Prospective Randomized Trial of High Dose Versus Standard Dose Stereotactic Radiotherapy for Pain Control in Patients With Bone Metastases

Status unknown Phase 2 Last updated 21 August 2019
What this trial tests

Phase 2 trial testing Stereotactic Radiotherapy in Bone Metastases in 302 participants. Status unknown.

Timeline
30 August 2019
Primary endpoint
30 August 2021
30 August 2021

Quick facts

Lead sponsorNational Taiwan University Hospital
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment302
Start date30 August 2019
Primary completion30 August 2021
Estimated completion30 August 2021

Drugs / interventions tested

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

20 and older, any sex, with Bone Metastases or Radiotherapy Side Effect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the present study, we will prospectively evaluate the pain response and treatment failure rate to determine the most favorable radiation dose in single fraction stereotactic radiotherapy using the modern highly conformal technique for bone metastases. Our findings should be able to provide evidence-based recommendation to support the utilization of single fraction radiotherapy for value-based oncology practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Stereotactic Radiotherapy

Trials testing the same drug.

Other recruiting trials for Bone Metastases

Currently open trials in the same condition.

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04063254.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing